Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FWBI

First Wave BioPharma (FWBI) Stock Price, News & Analysis

First Wave BioPharma logo

About First Wave BioPharma Stock (NASDAQ:FWBI)

Key Stats

Today's Range
N/A
50-Day Range
$2.60
$4.63
52-Week Range
N/A
Volume
56,500 shs
Average Volume
212,944 shs
Market Capitalization
$7.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.00
Consensus Rating
Moderate Buy

Company Overview

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients; and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Receive FWBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for First Wave BioPharma and its competitors with MarketBeat's FREE daily newsletter.

FWBI Stock News Headlines

ENTO Entero Therapeutics, Inc.
How to trade Cryptos using Elliott Wave
This company will win the AI race
Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse.
See More Headlines

FWBI Stock Analysis - Frequently Asked Questions

First Wave BioPharma, Inc. (NASDAQ:FWBI) issued its quarterly earnings data on Sunday, November, 14th. The company reported ($13,734.00) EPS for the quarter, missing analysts' consensus estimates of ($3,318.00) by $10,416.00.

First Wave BioPharma's stock reverse split on Monday, December 18th 2023. The 1-20 reverse split was announced on Monday, December 18th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that First Wave BioPharma investors own include Tesla (TSLA), HIVE Digital Technologies (HIVE), Palantir Technologies (PLTR), Shopify (SHOP), BIOLASE (BIOL), Meta Platforms (META) and PayPal (PYPL).

Company Calendar

Last Earnings
11/14/2021
Today
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FWBI
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$36.00
High Stock Price Target
$36.00
Low Stock Price Target
$36.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-15,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$6.54 per share

Miscellaneous

Free Float
2,463,000
Market Cap
$7.34 million
Optionable
Not Optionable
Beta
1.28
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

This page (NASDAQ:FWBI) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners